Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658359 · ClinicalTrials.gov registry record · Phase 2
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
NCT00658359 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 178 participants.
The verdict
NCT00658359, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
Study Summary
This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will follow transplant patients through Month 36 posttransplant. Patients will continue their study medications that were previously assigned.
Interventions
- DRUG Cyclosporine
- DRUG CP-690,550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2008-08 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00658359
The ClinicalTrials.gov registry entry for NCT00658359 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclosporine is the first listed.
NCT00658359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00658359 about?
NCT00658359 is a clinical study titled "Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients". This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will follow transplant patients through Month 36 posttransplant. Patients will continue their study medicatio...
What is the current status of trial NCT00658359?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2008-08. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00658359?
The interventions under investigation include: Cyclosporine (DRUG), CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT00658359?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.